Primary Site >> Pancreatic Cancer
Gene >> SLC44A4
|
|
|---|---|
|
Ref: Novel agents in the treatment of pancreatic adenocarcinoma. PMID: 23474556 |
Ref: A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. PMID: 26994014 Ref: The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer. PMID: 27550944 |